Zydus
dedicated to life

Cadila
Healthcare Limited

**Regd. Office :**
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

June 19, 2017

**BSE Limited**
1st Floor, P J Towers,
Dalal Street,
Mumbai – 400 001

**National Stock Exchange of India Limited**
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051

Re.: **Press Release**

Dear Sir / Madam,

We enclose herewith a copy of press release dated June 19, 2017 titled "Zydus receives final approval from the USFDA for Eletriptan Hydrobromide Tablets".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**

**UPEN H. SHAH**
**COMPANY SECRETARY**

CADILA HEALTHCARE LIMITED AHMEDABAD

Zydus
dedicated to life

Press Release

Press Release

Press Release

# Zydus receives final approval from the USFDA for Eletriptan Hydrobromide Tablets

*Ahmedabad, 19 June 2017*

Zydus Cadila has received the final approval from the USFDA to market Eletriptan Hydrobromide Tablets, 20 mg (base) and 40 mg (base).

The drug which is used in the treatment of migraine, will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

***

For further information please contact :
**The Corporate Communications Department**

**Cadila Healthcare Limited**
'Zydus Tower', Satellite Cross Roads, Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines) Fax : +91-79-2686 2365 www.zyduscadila.com
CIN-L24230GJ1995PLC025878